These include HR-positive/HER2-negative (HR+/HER2-), HR+/HER2+, HR-/HER2+, and triple-negative breast cancer (TNBC), which lacks estrogen receptor, progesterone receptor, and HER2 expression (Li et al., 2017). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.